Hannah M Linden

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/23125/publications.pdf Version: 2024-02-01



Ηλνινά Μινσεν

#	Article	IF	CITATIONS
1	Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2793-2799.	1.6	357
2	Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. Journal of Nuclear Medicine, 2003, 44, 1806-14.	5.0	151
3	Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4449-4457.	1.6	142
4	Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 4799-4805.	7.0	120
5	Quantitative Imaging in Cancer Clinical Trials. Clinical Cancer Research, 2016, 22, 284-290.	7.0	106
6	PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake. Clinical Cancer Research, 2011, 17, 2400-2409.	7.0	94
7	Attitudes Toward Participation in Breast Cancer Randomized Clinical Trials in the African American Community. Cancer Nursing, 2007, 30, 261-269.	1.5	59
8	Novel Methods and Tracers for Breast Cancer Imaging. Seminars in Nuclear Medicine, 2013, 43, 324-329.	4.6	52
9	Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 75S-80S.	5.0	43
10	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1219-1235.	0.8	30
11	Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clinics, 2018, 13, 415-422.	3.0	30
12	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Research, 2012, 2, 34.	2.5	27
13	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. Clinical Breast Cancer, 2019, 19, e283-e296.	2.4	24
14	Test–Retest Reproducibility of ¹⁸ F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network. Journal of Nuclear Medicine, 2019, 60, 608-614.	5.0	21
15	¹⁸ F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2â² Metastatic Breast Cancer. Journal of Nuclear Medicine, 2021, 62, 184-190.	5.0	20
16	Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, e143-e149.	2.4	15
17	Effect of 18F-FDG Uptake Time on Lesion Detectability in PET Imaging of Early-Stage Breast Cancer. Tomography, 2015, 1, 53-60.	1.8	12
18	Satisfaction with cancer care among American Indian and Alaska Natives in Oregon and Washington State: a qualitative study of survivor and caregiver perspectives. Supportive Care in Cancer, 2016, 24, 2437-2444.	2.2	11

Hannah M Linden

#	Article	IF	CITATIONS
19	18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. Breast Cancer Research, 2021, 23, 88.	5.0	11
20	Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer. Journal of Nuclear Medicine, 2017, 58, 560-562.	5.0	10
21	The Value of Establishing the Quantitative Accuracy of PET/CT Imaging. Journal of Nuclear Medicine, 2015, 56, 1133-1134.	5.0	8
22	Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New. Clinical Breast Cancer, 2015, 15, e277-e285.	2.4	6
23	Determinants of Guideline-Discordant Breast Cancer Care. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 61-70.	2.5	2
24	Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. Tomography, 2020, 6, 60-64.	1.8	2
25	Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer. Breast Cancer Research and Treatment, 2022, 194, 507-516.	2.5	Ο